This is the third pharmaceutical Rapid Collaborative Review (PTRCR19) published by EUnetHTA. This report describes REGN-COV2 for the treatment of COVID-19 patients.
In March 2021, after an Article 5(3) review the European Medicines Agency (EMA) endorsed the use of REGN-COV2 for the treatment of confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for COVID-19 and who are at high risk of progressing to severe COVID-19. The EUnetHTA Rapid Collaborative Review aims to define, according to the national requirements of the EUnetHTA partners, the PICO, an overview of available evidence and Evidence gaps of REGN-COV2 in the target patient populations with relevant comparators.
For any questions regarding the Rapid Collaborative Review, please contact firstname.lastname@example.org.
Please find the review here:
PTRCR19 – Final Rapid Collaborative Review
This website was produced under the Third EU Health Programme through a service contract with the European Health and Digital Executive Agency (HaDEA) acting under the mandate from the European Commission. The information and views set out in this website are those of the author(s) and do not necessarily reflect the official opinion of the Commission/Executive Agency. The Commission/Executive Agency do not guarantee the accuracy of the data included in this website. Neither the Commission/Executive Agency nor any person acting on the Commission’s/Executive Agency’s behalf may be held responsible for the use which may be made of the information contained therein.
©2021 EUnetHTA All rights reserved.